Stock Screener App

Frei -

Installieren

26.12

1.18% -0.26

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake - Stock Titan

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27. - Pluang

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside - TradingView

Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE) - Seeking Alpha

Ultragenyx (RARE): AQR Capital discloses 6.56M-share, 6.66% ownership stake - Stock Titan

Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx (RARE) Q2 2026 Earnings Call Transcript - AOL.com

(RARE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

HC Wainwright Has Bullish Estimate for RARE Q3 Earnings - MarketBeat

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss - Sahm

Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRARE (PR Newswire) - Aktiellt

Ultragenyx and Baylor Research Institute Settle DOJOLVI Generic Patent Lawsuit with Esjay Pharma - Kalkine Media

Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma - Investing.com South Africa

Form 8K Ultragenyx For: 11 August By Investing.com - Investing.com South Africa

Ultragenyx to license generic DOJOLVI to Esjay starting Jan 1, 2033 under settlement - TradingView

H.C. Wainwright reiterates Ultragenyx stock rating on strong quarter By Investing.com - Investing.com UK

H.C. Wainwright reiterates Ultragenyx stock rating on strong quarter - Investing.com Nigeria

Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright - MarketBeat

Sei Investments Co. Sells 61,632 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Is Q2 Revenue Growth And Narrower Loss Altering The Investment Case For Ultragenyx Pharmaceutical (RARE)? - Yahoo Finance

Ultragenyx at $25.91: Deep Discount or Value Trap as Q2 Losses Mount? - finance.biggo.com

Has Ultragenyx Pharmaceutical (RARE) Fallen Far Enough To Avoid Overvaluation? - Yahoo Finance

Ultragenyx Pharmaceutical (RARE) Following Q2 Results Looks Close To Fair Value - Yahoo Finance

RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits

Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen - MarketBeat

State Street Corporation (RARE) discloses 6.3% Ultragenyx ownership on Schedule 13G - Stock Titan

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

ULTRAGENYX PHARMACEUTICAL INC. : WELLS FARGO CUTS TARGET PRICE TO $45 FROM $47 - webull.com

Ultragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burn - Sahm

BlackRock, Inc. Buys Ultragenyx Pharmaceutical Inc (RARE) -- Sha - GuruFocus

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company - MarketBeat

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y - Yahoo Finance

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up on Strong Earnings - MarketBeat

Ultragenyx Pharmaceutical Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed - marketscreener.com

Ultragenyx Pharmaceutical Inc. Q2 2026: Revenue $214M, EPS $(0.90) — 10-Q Summary - TradingView

Ultragenyx Pharmaceutical Inc (RARE) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights - Yahoo Finance

Ultragenyx (RARE) CFO Howard Horn Sells 4,696 Shares - GuruFocus

Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Earnings Results, Beats Estimates By $0.32 EPS - MarketBeat

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q2 Loss of $0.90 per Share, vs. FactSet Est $1.22 Loss - marketscreener.com

Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q2 Revenue $214.0M, vs. FactSet Est of $183.1M - marketscreener.com

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update - Yahoo Finance

Ultragenyx Pharmaceutical Inc. (RARE) CLO sells 1,900 shares at $24.92 - Stock Titan

Ultragenyx (RARE) CFO sells stock under 10b5-1 plan, keeps 96,295 shares - Stock Titan

The Manufacturers Life Insurance Company Boosts Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Guggenheim Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring A 113% Upside Potential - directorstalkinterviews.com

Bank of New York Mellon Corp Acquires 42,419 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Two FDA action dates and Angelman syndrome data are ahead for Ultragenyx - Stock Titan

Ultragenyx (RARE) insider Howard Horn files to sell 4,696 shares - Stock Titan

Ultragenyx Pharmaceutical Inc. $RARE Holdings Raised by Renaissance Technologies LLC - MarketBeat

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Ultragenyx Pharmaceutical (RARE) and Bausch Health Companies (BHC) - The Globe and Mail

Vanguard Portfolio Management (RARE) discloses 6.85M-share Ultragenyx stake on 13G/A - Stock Titan

BlackRock (RARE holder) discloses 8.3% Ultragenyx stake in amended 13G - Stock Titan

Ultragenyx Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Ultragenyx in the spotlight as earnings test growth comeback - Investing.com

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Danaher (DHR) - The Globe and Mail

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline - Yahoo Finance UK

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring Nearly 100% Potential Upside - DirectorsTalk Interviews

Ultragenyx Will Webcast Its August 4 Corporate Update - Stock Titan

RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease - STAT

Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

MRNA

$63.45

0.39%

ROIV

$36.15

0.33%

RPRX

$58.77

0.12%

INSM

$123.78

1.98%

ALNY

$227.36

0.09%

ONC

$346.68

2.57%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters